It has been revealed that the presence of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer can aid in independently predicting the risk of recurrence of the disease in patients who had undergone surgery after neoadjuvant chemotherapy. This may represent an important novel stratification factor for future post-neoadjuvant trials.
Patients with triple-negative breast cancer with residual disease have an exceptionally high risk of recurrence and novel therapies and technologies are thus essential, including those that can potentially predict the risk of relapse. ctDNA or plasma-derived tumour DNA is being explored as a way to detect cancer, guide treatment, and monitor patients during remission as the presence of ctDNA can signal the presence of cancer.
Researchers analysed plasma samples collected from 196 patients enrolled in the BRE12-158 clinical trial, which studied genomically directed therapy versus physician’s choice of treat...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide Next Article
Palbociclib not statistically superior to capecitabine in PFS »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.